Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice Publisher Pubmed



Abbaspanah B1 ; Reyhani S2 ; Mousavi SH3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Royan Stem Cell Technology Company, Cord Blood Bank, Tehran, Iran
  2. 2. Department of Laboratory Sciences, School of Allied Medical sciences, Tehran University of Medical sciences, Tehran, Iran
  3. 3. Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical sciences, Tehran, Iran

Source: Current Stem Cell Research and Therapy Published:2021


Abstract

Mesenchymal Stem Cells (MSCs) enable a novel approach to stem cell therapy. Bone Marrow (BM) was the first source used in MSCs therapy. However, BM has a number of key limitations as a source of MSCs, such as the existence of only a small number of MSCs in the tissue; the painful, ethically problematic, and invasive nature of the associated collection process; and a de-crease in MSC specifications as the age of donors increases. As a result, there has been increasing scholarly attention towards identifying alternative sources for MSCs. In specific, Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) have been identified as a valuable source from which MSC may be obtained with potentially fewer ethical issues. MSCs can regulate the immune response, promote tissue repair, increase regeneration, and improve anticancer effects. Thus, they are significant allogenic and autologous representatives for curing malignant and non-malignant disorders. In this review, therefore, the prospective applications for curing autoimmune disorders will be considered. © 2021 Bentham Science Publishers.
Other Related Docs
18. Multipotent Stem Cell and Current Application, Acta Medica Iranica (2017)
32. Introduction to Stem Cells and Immunity, Comprehensive Hematology and Stem Cell Research: Volume 1-5 (2024)
35. A Markov Decision Process for Modeling Adverse Drug Reactions in Medication Treatment of Type 2 Diabetes, Proceedings of the Institution of Mechanical Engineers# Part H: Journal of Engineering in Medicine (2019)